{"id":596260,"date":"2022-04-18T17:08:02","date_gmt":"2022-04-18T17:08:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=596260"},"modified":"2022-04-18T17:08:02","modified_gmt":"2022-04-18T17:08:02","slug":"ocular-inflammation-and-pain-pipeline-review-analysis-into-the-novel-and-emerging-therapeutic-drugs-clinical-trials-and-treatment-outlook-key-companiesoculis-formosa-pharma-tarsius-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ocular-inflammation-and-pain-pipeline-review-analysis-into-the-novel-and-emerging-therapeutic-drugs-clinical-trials-and-treatment-outlook-key-companiesoculis-formosa-pharma-tarsius-and-others_596260.html","title":{"rendered":"Ocular Inflammation and Pain Pipeline Review: Analysis into the Novel and Emerging Therapeutic Drugs, Clinical Trials, and Treatment Outlook | Key Companies-Oculis, Formosa Pharma, Tarsius, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ocular Inflammation and Pain Pipeline Review: Analysis into the Novel and Emerging Therapeutic Drugs, Clinical Trials, and Treatment Outlook | Key Companies-Oculis, Formosa Pharma, Tarsius, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Ocular Inflammation and Pain Pipeline Review: Analysis into the Novel and Emerging Therapeutic Drugs, Clinical Trials, and Treatment Outlook | Key Companies-Oculis, Formosa Pharma, Tarsius, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cOcular Inflammation and Pain Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ocular Inflammation and Pain Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Ocular Inflammation and Pain Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Ocular Inflammation and Pain Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/ef5b5c36ef1b6c2175c70004924dbe62.jpg\" alt=\"Ocular Inflammation and Pain Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ocular-inflammation-and-pain-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Ocular Inflammation and Pain Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Ocular Inflammation<\/strong> and Pain with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Ocular Inflammation and Pain Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Ocular Inflammation and Pain key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Ocular Inflammation and Pain Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Ocular Inflammation and Pain market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211; @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ocular Inflammation and Pain Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>As per DelveInsight, the expected launch of the pipeline therapies will fuel the Ocular Inflammation and Pain market growth in the coming years.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Ocular Inflammation and Pain Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oculis Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Formosa Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tarsius Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Reata Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alcon Research<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eyepoint Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ocular Inflammation and Pain Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">OCS-01<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">APP13007<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TRS 01<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DEXYCU<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nepafenac<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Omaveloxolone<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Ocular Inflammation and Pain&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Ocular Inflammation and Pain Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Ocular Inflammation and Pain &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Ocular Inflammation and Pain Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Ocular Inflammation and Pain Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Ocular Inflammation and Pain Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Ocular Inflammation and Pain Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Ocular Inflammation and Pain Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Ocular Inflammation and Pain Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Ocular Inflammation and Pain Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Ocular Inflammation and Pain Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Ocular Inflammation and Pain Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ocular-inflammation-and-pain-pipeline-insight<\/a><\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pars-plantis-market\">Pars Plantis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong>Pars Plantis Market<\/strong>&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology, the Pars Plantis market size, and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ocular-inflammation-and-pain-pipeline-review-analysis-into-the-novel-and-emerging-therapeutic-drugs-clinical-trials-and-treatment-outlook-key-companiesoculis-formosa-pharma-tarsius-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ocular-inflammation-and-pain-pipeline-review-analysis-into-the-novel-and-emerging-therapeutic-drugs-clinical-trials-and-treatment-outlook-key-companiesoculis-formosa-pharma-tarsius-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cOcular Inflammation and Pain Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ocular Inflammation and Pain Market. The Ocular Inflammation and Pain Pipeline report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ocular-inflammation-and-pain-pipeline-review-analysis-into-the-novel-and-emerging-therapeutic-drugs-clinical-trials-and-treatment-outlook-key-companiesoculis-formosa-pharma-tarsius-and-others_596260.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-596260","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=596260"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=596260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=596260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=596260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}